Use of antidepressants during pregnancy and neonatal outcomes: An umbrella review of meta-analyses of observational studies
Publication date: Available online 26 February 2020Source: Journal of Psychiatric ResearchAuthor(s): Annalisa Biffi, Anna Cantarutti, Federico Rea, Anna Locatelli, Rinaldo Zanini, Giovanni Corrao
Authors: Andrade C Abstract Many observational studies have found an association between antidepressant drug prescription during pregnancy and neurodevelopmental disorders such as autism spectrum disorder, attention-deficit/hyperactivity disorder, and intellectual disability. The results of such studies cannot be considered conclusive because of the possible presence of inadequately measured, unmeasured, and unknown confounds. In this context, maternal anemia before or at but not after 30 weeks of gestation was recently associated with an increased risk of all 3 of these neurodevelopmental disorders. Additionally, ...
Conclusion: These finds highlight the role of ERAP1 in the pathogenesis of preeclampsia. PMID: 32239976 [PubMed - as supplied by publisher]
CONCLUSIONS: Low RBC folate is associated with perinatal factors, including high maternal cotinine levels, body mass index, stress, and depression. The effect of low folate levels among smokers cannot be overemphasized, considering that tobacco products not only reduce folate levels but also decrease the bioutilization of folate. PMID: 32239227 [PubMed - as supplied by publisher]
ConclusionDispensing of potentially harmful medicines in pregnancy in New Zealand was low, particularly for Category X medicines. However, exposure did increase over the study timeframe. The inclusion of pregnancies that did not progress past early pregnancy better reflects population-level pregnancy exposure to potentially teratogenic medicines.
Authors: Gallo L, Ruggiero A, Balato A, Megna M, Fabbrocini G PMID: 32233899 [PubMed - as supplied by publisher]
Publication date: Available online 29 February 2020Source: Journal of Minimally Invasive GynecologyAuthor(s): Jing Xiao, Kristi Fu, Kristina Duan, Junling Wang, Sowmya Sunkara, Xiaoming Guan
Publication date: Available online 2 April 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Gabriele Saccone, Floriana Carbone, Fulvio Zullo
CONCLUSION: Rates of perinatal complications in our series are more reassuring than the ubiquitously quoted rates from small and dated studies. The diagnosis of primary hyperparathyroidism may be easily missed during pregnancy, owing to its non-specific presentation. A high index of suspicion and measurement of ionized calcium levels is encouraged, especially for patients with excessive nausea and vomiting, nephrolithiasis, atypical presentations of hypertensive disorders, or isolated polyhydramnios. Mild degrees of calcium derangement do not preclude adverse perinatal outcomes. Surgery appears to be safe, even in the thir...
Publication date: Available online 2 April 2020Source: Trends in Endocrinology &MetabolismAuthor(s): Jeremy Gingrich, Elvis Ticiani, Almudena Veiga-Lopez
SOUTH SAN FRANCISCO, CA, April 3, 2020 – Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson &Johnson, today announced that CHEST, the official publication of the American College of Chest Physicians, published results from an expert Delphi consensus survey that help provide additional insights for physicians to advance the care of patients with pulmonary arterial hypertension (PAH).The Prostacyclin International Expert Panel developed the consensus opinions based on common clinical scenarios in which they considered adding oral prostacyclin pathway agents (PPAs), including UPTRAVI®...